@JimCatto

Father & husband. Urological surgeon @SheffieldHosp. Academic @sheffielduni. @NIHRcommunity Research Professor. @EUplatinum He/Him. Views my own

 Sheffield, England
shef.ac.uk/oncology/staffprofiles/catto
Joined February 2012
  • Tweets8.5K
  • Following649
  • Followers6.7K
332Media
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cance... sciencedirect.com/science/ar…
12
2
47
5,876
The medical community has a perception that breast cancer screening GOOD and prostate cancer screening BAD. Internist Gil Welch provides data showing just how flawed that perception is.
1
18
3
42
7,008
Great opportunity to work on #pancreaticcancer Come and work in @sheffielduni and @TUOS_Cancer with Stephen Bradley. jobs.ac.uk/job/DNM666/resear…
3
558
Girl with cancer hikes 11 miles for tumour charity bbc.in/42RSCgT

Sheffield girl with tumour hikes 18km for childrens' charity

Thalia, 12, says she wants to prove having a brain tumour "can't stop you doing what you love".

bbc.com
5
19
3,953
New post alert: NIHR Clinical Lectureship in Urology at the @sheffielduni just advertised. jobs.shef.ac.uk/sap/bc/webdy…
4
10
1,960
Real-world outcomes for high-risk non-muscle-invasive #BladderCancer: screened patients for the BRAVO trial @S_Conroy91 @JimCatto doi.org/10.1111/bju.16516
5
2
22
6,555
New review on plant-based diets & urological health is out today in @NatRevUrol-Favorable associations reported for multiple benign & malignant conditions 🍆 Thx collabs @DrJBorin @gvenigalla @med_manish @natgupta @Putnam_Cole @KatherineAminMD Full-text: nature.com/articles/s41585-0…
1
20
2
68
6,801
Tremendous effort by @slernerbcmedu1 & colleagues on this @SWOG S1011 trial. Practice changing trial. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer nejm.org/doi/full/10.1056/NE… @SvatekRob @PoharKamal @AnneSchuckmanMD @UroDocAsh @montypal @garysteinbergmd

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer | NEJM

Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder canc...

nejm.org
5
27
1
104
10,134
Just in @NEJM 👉the primary results of ph3 @SWOG 1011 trial (n=592)👉in pts with muscle-invasive #bladdercancer undergoing radical cystectomy👉standard lymphadenectomy is sufficient (extended lymphadenectomy did not improve survival outcomes)👇Link: tinyurl.com/bdh4z5n7 Congrats @slernerbcmedu1 & the stellar team: @siadaneshmand @UroDocAsh @montypal Cc'ing @urotoday @BladderCancerUS @ALLIANCE_org @eaonc
61
6
146
23,713
In a multicenter randomized trial, tranexamic acid did not reduce blood transfusion during radical cystectomy. ja.ma/3XMBIMV
1
27
6
57
26,166
Great to have @KariTikkinen in @sheffielduni today talking about #thromboembolism and surgery @ProfSyedHussain
1
2
1
27
1,770
🚨FGFR Inhibition in Urothelial Carcinoma🚨 @EUplatinum 👉Much of the focus on FGFR in UC has been related to targeted therapy w/ erdaftitinib. ✅However, the research base for FGFR alterations is extensive ✍️This expert review discusses the molecular & clinical associations w/ FGFR & future treatment potentials @GGiannarini @UrogerliMD @JimCatto @siadaneshmand @FaltasLab @UroDocAsh @AndreaNecchi @JoshMeeks @BladderCancerUS @urotoday @UroOnc
7
24
2,994
Presented at #ESMO24 and published simultaneously @TheLancetOncol: thelancet.com/journals/lanon… The randomised ph2 UpFrontPSMA study: Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive #prostatecancer
28
5
65
23,060
Exited to share the first results from the TOMBOLA trial presented at #ESMO24 by @JBjerggaard. We used tumor informed (WES; ddPCR) ctDNA analysis to guide Atezolizumab treatment after cystectomy using longitudinally collected blood samples. Key findings: •CtDNA-negative patients: 98% RFS at 1 year •~50% are ctDNA-positive •CtDNA-positive patients: 75% RFS at 1 year •55% of Atezolizumab-treated patients cleared ctDNA & have no evidence of disease Conclusion: ctDNA shows promise for treatment de-escalation (ctDNA-) and patient selection for adjuvant therapy (ctDNA+) @Karin_Dem @IverNordentoft @SiaLindskrog @TrineStrandgaa1 @cancer_dk @DCCCcancer @CtdnaDK @AUHdk @AarhusUni
12
40
2
98
7,180
The ph2 SR-4 trial shows that TAR-200 + #cetrelimab neoadjuvant therapy revealed pCR and pOR rates of 42% and 60%, respectively, with a manageable safety profile. These findings support the addition of TAR-200 to anti-PD-1 tx in pts with #MIBC! @myESMO #ESMO2024 @OncoAlert
18
30
3,849
jim catto retweeted
NEJM
@NEJM15 Sep 2024
Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone. Full NIAGARA trial results: nej.md/4gmAqk3 #ESMO24
4
101
11
203
48,145
Pushing the boundaries for the standard of care in MIBC; practice-changing advancement @tompowles1 @MattGalsky @JimCatto nejm.org/doi/abs/10.1056/NEJ… #ESMO24

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer | NEJM

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve...

nejm.org
Tom Powles
@tompowles115 Sep 2024
Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 @NEJM
1
6
22
2,710
After SunRISe-1 at #ESMO24 -- the ever expanding treatment options for BCG unresponsive NMBIC -- De Santis @urotoday
9
15
1,332
jim catto retweeted
NEJM
@NEJM15 Sep 2024
AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group. nej.md/4gh1b9D #ESMO24
Kaplan–Meier plots for disease-free survival in the intention-to-treat population.

ALT Kaplan–Meier plots for disease-free survival in the intention-to-treat population.

5
123
9
261
49,222
⚡️ LBA -- TAR-200 +/- CET & CET alone in BCG-unresp HR NMIBC: Updated results from SunRISe-1 @urotoday #ESMO24 C1: TAR-200 + CET (n=53) C2: TAR-200 alone (n=85) C3: CET alone (n=28) 📌CR rates: C1 - 68%; C2 - 84%; C3 - 46% 📌D/C rates: C1 - 23%; C2 - 6%; C3 - 7%
12
17
2,692
Clearance of ctDNA associated with improved outcomes in neoadjuvant RX with Durvalumab + tremilumab + EV (enfortumab) in #bladdercancer (cisplatin ineligible). Congrats @drakaki for the outstanding presentation at @myESMO #ESMO24 @OncoAlert @BladderCancerUS @urotoday
20
3
34
5,749
Load more